NorstellaLinQ: Refining Rare Disease Targeting with Real-World Data
A mid-sized pharmaceutical company faced the challenge of identifying patients for a rare disease and complex indication. Using MMIT’s NorstellaLinQ, the company refined patient targeting, uncovered detailed treatment journeys, and improved physician outreach and marketing efforts.
Patient Identification
Find rare disease patients with uncommon ICD-10 codes and biomarker tests.
Treatment Journey Mapping
Track diagnosis, treatment patterns, and care progression.
Intermediate-Risk Cancer Insights
Understand how specific patient subgroups are diagnosed and treated.
HCP Targeting
Identify physicians treating these conditions for precision marketing and outreach.